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Abstract
Background
Findings of cerebral cortical atrophy, white matter lesions and microhemorrhages have
been reported in high-altitude climbers. The aim of this study was to evaluate structural
cerebral changes in a large cohort of climbers after an ascent to extreme altitudes and to
correlate these findings with the severity of hypoxia and neurological signs during the climb.
Methods
Magnetic resonance imaging (MRI) studies were performed in 38 mountaineers before and
after participating in a high altitude (7126m) climbing expedition. The imaging studies were
assessed for occurrence of newWM hyperintensities and microhemorrhages. Changes of
partial volume estimates of cerebrospinal fluid, grey matter, and white matter were evalu-
ated by voxel-based morphometry. Arterial oxygen saturation and acute mountain sickness
scores were recorded daily during the climb.
Results
On post-expedition imaging no new white matter hyperintensities were observed. Com-
pared to baseline testing, we observed a significant cerebrospinal fluid fraction increase
(0.34% [95% CI 0.10–0.58], p = 0.006) and a white matter fraction reduction (-0.18% [95%
CI -0.32–-0.04], p = 0.012), whereas the grey matter fraction remained stable (0.16% [95%
CI -0.46–0.13], p = 0.278). Post-expedition imaging revealed new microhemorrhages in 3 of
15 climbers reaching an altitude of over 7000m. Affected climbers had significantly lower
oxygen saturation values but not higher acute mountain sickness scores than climbers with-
out microhemorrhages.
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Conclusions
A single sojourn to extreme altitudes is not associated with development of focal white mat-
ter hyperintensities and grey matter atrophy but leads to a decrease in brain white matter
fraction. Microhemorrhages indicative of substantial blood-brain barrier disruption occur in a
significant number of climbers attaining extreme altitudes.
Introduction
Altitude related medical problems are gaining importance and attention as an increasing num-
ber of trekkers and recreational climbers attempt ascents to very high (3500m to 5500m) or
extreme altitudes (>5500m) [1]. The possibility of long-term cerebral sequelae from exposure
to severe hypobaric hypoxia has been a topic of controversy for decades [2–4]. Structural cere-
bral changes detected by magnetic resonance imaging (MRI) have been reported after high-
altitude climbs [5–12]. These include findings of cortical atrophy and white matter hyperinten-
sities in mountain climbers ascending to altitudes between 4810 m and 8848 m, the majority of
which did not suffer from cerebral forms of high altitude illness, such as severe acute mountain
sickness (AMS) or high altitude cerebral edema (HACE) [5, 7–10]. MRI studies of climbers
after the occurrence of clinical overt HACE have shown reversible findings of vasogenic edema
[11] and of microhemorrhages [6, 12], both with a predilection for the splenium of the corpus
callosum. Microhemorrhages in the corpus callosum after high altitude exposure represent evi-
dence for a disruption of the blood-brain barrier and have been postulated to be specific for
HACE [12].
Published imaging studies in high altitude climbers represent case series or cohort studies in
a small number of subjects and data on severity of hypoxia and signs and symptoms of high
altitude illness was not prospectively collected. Often, imaging was obtained only after high-
altitude exposure and non-climbers served as controls [6–8, 10, 11, 13]. The retrospective clini-
cal diagnosis of cerebral forms of high altitude illness occurring in the context of challenging
conditions during a high altitude climb can be difficult, even when applying recommended
scoring systems [14, 15].
The aim of the study at hand is to evaluate the occurrence of structural cerebral changes in a
large group of climbers by comparison of MRI studies before and after ascent to extreme alti-
tude and to correlate these findings with prospectively collected data on severity of hypoxia
and signs and symptoms of cerebral forms of high altitude illness during the climb. Based on
the results of previous studies, we hypothesized that structural cerebral changes such as cortical
atrophy and white matter hyperintensities would occur more frequently in the most hypoxic
subjects and that microhemorrhages would be detectable in subjects suffering from clinically
apparent HACE during the climb.
Material and Methods
Setting
The prospective observational cohort study was performed in the context of the Swiss High
Altitude Medical Research Expedition 2013 to Mount Himlung Himal (7126m). Baseline and
post-expedition testing was in two groups in Switzerland (550m) eight and nine weeks before
the start of the expedition and four and five weeks after return. No supplementary oxygen was
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used during the climb. Throughout the entire expedition food and fluids were provided in
unlimited amounts to the participants.
Participants
The study included forty healthy subjects aged between 18 and 70 years. Subjects had to be
healthy, aged between 18 and 70 years, physically fit and have basic mountaineering experience
and skills. Subjects with a history of any neurological, cardiac or respiratory disease, diabetes
mellitus type I or II, head trauma or who developed severe AMS, HACE or high altitude pul-
monary edema (HAPE) after a rapid ascent (< 3 nights) at altitudes below 3500m and subjects
on regular medication with beta-blockers, ACE-inhibitors, nitrates and calcium antagonists,
corticosteroids, anti-inflammatory drugs, platelet aggregation inhibitors and anticoagulants
were excluded from the study.
Study size
The number of subjects was determined by the maximum number of climbers that could par-
ticipate in the expedition when considering the logistical and safety constraints of an ascent to
extreme altitudes.
MR imaging technique
MRI of the brain was performed on a 3 T MR scanner (Magnetom Verio, Siemens, Erlangen,
Germany) with a 32-channel head coil during baseline and post-expedition testing. The MRI
protocol included 1 mm 3D fluid attenuated inversion recovery (FLAIR,TR/TE 5000/395ms),
axial susceptibility-weighted imaging (SWI, slice thickness 1.2mm, TR/TE 28/20ms), and 1mm
3Dmodified driven equilibrium fourier transform (MDEFT) sequences (TR/TE 7.92/2.48 ms).
1mmmultiplanar reformations of FLAIR and MDEFT sequences in axial and coronal planes
were made. SWI minimum-intensity projections (MinIP, slice-thickness 9.6mm) were auto-
matically calculated by the scanner. Images were visually assessed for white matter lesions
(WML) (FLAIR), signs of cortical atrophy such as widening of sulci (MDEFT), and microhe-
morrhages (SWI). Number, size, configuration and distribution of WML were recorded. Sus-
ceptibility-weighted images were scrutinized for focal hypointense artefacts suggestive of
microhemorrhages.
Comparison between pre- and post-expedition MR images was performed in consensus
reading by two experienced neuroradiologists blinded to clinical and physiological data (MH,
RK). For a more detailed evaluation of possible brain volume changes after altitude exposure,
partial volumes of cerebrospinal fluid (CSF), grey matter (GM), and white matter (WM) were
estimated on high-resolution T1-weighted images (MDEFT) (software package FSL, version
5.0, Oxford Centre for Functional MRI of the Brain [FMRIB]). All voxels were classified into
three tissue classes (CSF, GM andWM) with the sum of probabilities equal to one. Partial vol-
ume estimates (PVE) for each tissue class were calculated by integrating the tissue class proba-
bilities voxelwise over the whole volume and expressed as fractions of total brain volume.
Physiological changes of PVEs due to aging of subjects between examinations were accounted
for by comparison with reference data from adult non-climbers [16, 17].
Clinical parameters
Subjects baseline characteristics including a detailed medical history and the number of nights
spent at an altitude of>4000m at any time before study inclusion was assessed during baseline
testing. During the expedition symptoms of AMS were assessed daily using the cerebral score
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of the environmental symptoms questionnaire score (AMS-c) and the Lake Louise AMS proto-
col (AMS LL) [18]. An AMS-c0.7 or an AMS LL 3 plus the presence of headache define
occurrence of AMS. Finger pulse oximetry was performed in the morning and evening at rest
in a sitting position (Onyx 9500 SportStat, Nonin Medical, Plymouth, USA) after having stable
values during at least 3 min. AMS scores and oxygen saturation (SpO2) were recorded in a
research diary by each subject. Subject groups were accompanied by one or more expedition
physicians at all times who monitored the climbers for occurrence of altitude related illnesses
and provided appropriate treatment. AMS treatment consisted of single doses of ibuprofen
and/or acetaminophen and occurred after AMS scoring. Prophylactic use of analgesics or the
use of acetazolamide was not permitted and not supplied to the subjects.
Statistics
Clinical data is presented as mean and standard deviation (SD) or median and lower and upper
limit of the interquartile range (IQR) for parametric and non-parametric data. For compari-
sons of measurements on different altitudes and group comparisons Kruskal-Wallis test fol-
lowed by Dunn's Multiple Comparison or Mann-Whitney U-Test was used. One-sample t-test
was used to test if mean changes of PVE fractions of different brain tissue classes significantly
differed from zero. We assumed a physiological age-related change of CSF, GM andWM frac-
tion of 0.065%, -0.058% and 0.00%, respectively during the 119 day period between baseline
and post-expedition testing [16, 17]. Pearson product-moment correlation coefficient with
false discovery rate (FDR) correction was computed to assess the relationship between PVE
fraction changes and subject characteristics and altitude measurements. For all analyses a p-
value of<0.05 was considered statistically significant. Statistical analysis was performed using
standard statistical packages (IBM SPSS Statistics Version 20).
Ethics approval: The study was approved by the institutional review board of the Canton of
Bern, Switzerland. Written informed consent was obtained from all subjects before enrolment.
Results
Participant
One subject was excluded from the expedition due to the incidental finding of a brain caver-
noma and one subject refused post-expedition imaging due to claustrophobia. A total of 38
subjects, 20 male and 18 female with a mean age of 45.4 years (median 47.5, range 24–69) with
a complete set of MRI were included for further analysis.
Course of the expedition and clinical findings
The climbers reached the Himlung basecamp (4800m) on day 5, camp 1 (5465m) on day 10,
camp 2 (6025m) on day 11 of the expedition. Camp 3 (7050m) was reached on day 21 and 22
and the summit (7126m) on day 22 and 23 by the two expedition groups. Maximum altitude
for overnight stay was camp 1 in 3 subjects, camp 2 in 19 subjects and camp 3 in 15 subjects.
The summit was reached by 13 climbers. Detailed subject characteristics and relevant parame-
ters regarding altitudes, AMS scores and oxygen saturation of subjects stratified by occurrence
of new MRI findings (described below) is provided in Table 1. Fig 1 shows the results of daily
SpO2 measurements during the expedition. Table 2 summarizes measurements of oxygen satu-
ration and reported AMS scores at different altitudes between basecamp and camp 3. All indi-
vidual SpO2 measurements, AMS scores and single AMS items collected during the expedition
are reported in S1 Table. The main analysis revealed a significant decrease in oxygen saturation
with increasing altitude, and concomitant increase of AMS scores and incidence of reported
Brain Changes after Climbing to Extreme Altitudes
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Table 1. Subject characteristics and relevant parameters regarding altitudes, AMS scores and oxygen saturation.
Subject
ID
Age
(years)
Gender Maximal
sleep
altitude
(m)
Maximal
altitude
reached
(m)
Lowest
SpO2
(%)
Number of
days
SpO2<75%
Maximal
AMS-c
Number
of days
AMS-c
>0.7
Maximal
AMS LL
Number
of days
AMS LL
>2
highest altitude
reached during
summit attempt;
reason for
aborting climb
1 32 f 6025 6025 65 5 0.957 1 8 15 6025m; exhaustion
2 30 m 7050 7126 61 4 1.078 1 6 8 summit
3 53 m 7050 7126 56 8 0.179 0 4 10 summit
4 54 m 6025 6025 71 2 0.269 0 4 4 6025m; AMS,
exhaustion
5 56 f 6025 6025 64 3 0.497 0 7 7 no summit attempt
due to severe
exhaustion at 6025
during
acclimatisation
period
6 32 f 6025 6900 66 6 0.418 0 5 6 6900m,
hypothermia,
exhaustion
7 36 m 5465 5800 71 8 2.895 3 9 8 5800m, mild AMS,
exhaustion
8 47 m 7050 7126 65 8 1.755 1 2 0 summit
9 43 f 7050 7050 66 2 0.349 0 0 0 6900m, dyspnoea,
possible HAPE
10 31 f 7050 7126 56 6 2.626 2 10 10 summit
11 27 f 7050 7126 67 4 0.298 0 0 0 summit
12 63 m 6025 6350 62 13 0.643 0 7 13 6360m, mild to
moderate AMS
13 58 m 7050 7126 65 5 0.090 0 3 2 summit
14 48 f 6025 6025 81 0 0.874 1 6 6 no summit attempt
due to AMS and
exhaustion at 6025
during
acclimatisation
period
15 62 m 6025 6025 72 1 0.273 0 3 2 5600m; dyspnoea
and exhaustion,
subsequent clinical
and radiologic
ﬁnding of central
pulmonary
embolism
16 48 m 6025 6250 67 5 1.508 4 9 10 6250m; moderate
AMS
17 57 f 6025 6025 72 5 1.090 2 6 7 6000m; metatarsal
fracture during
summit attempt
18 25 f 7050 7126 54 6 0.855 1 5 5 summit
19 58 f 7050 7126 62 0 0.333 0 3 2 summit
20 42 f 6025 6900 54 6 0.698 0 4 4 6900m, frost bite
and hypothermia
21 47 m 7050 7126 65 6 0.608 0 6 8 summit
22 57 m 7050 7126 65 4 1.271 1 8 7 summit
23 52 f 6025 6025 72 1 0.343 0 5 7 5600m, exhaustion
(Continued)
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AMS scores above the diagnostic cut-off at higher altitudes compared to BC values. However,
post-hoc analysis did not demonstrate a significant difference in oxygen saturation and AMS-c
between camp 2 and camp 3 and of AMS LL between basecamp, camp 1 and camp 2 compared
Table 1. (Continued)
Subject
ID
Age
(years)
Gender Maximal
sleep
altitude
(m)
Maximal
altitude
reached
(m)
Lowest
SpO2
(%)
Number of
days
SpO2<75%
Maximal
AMS-c
Number
of days
AMS-c
>0.7
Maximal
AMS LL
Number
of days
AMS LL
>2
highest altitude
reached during
summit attempt;
reason for
aborting climb
24 26 f 5465 5600 73 3 0.267 0 6 2 5600m;
exhaustion, lack of
motivation
25 53 f 6025 6025 70 2 0.411 0 8 6 no summit attempt,
due to cardiac
arrhythmia during
acclimatisation
period
26 62 m 7050 7126 73 1 0.569 0 3 2 summit
27 36 f 6025 6025 65 4 1.112 1 8 12 6025m;
exhaustion, fear of
difﬁcult conditions
28 48 m 6025 6900 71 1 0.700 0 7 9 6900m;
accompanied
descent of partner
with frostbite and
hypothermia
29 37 f 6025 6025 72 1 0.564 0 6 5 no summit attempt,
cardiac arrhythmia
during
acclimatisation
period
30 35 f 6025 6025 54 9 1.011 2 9 9 5600;m
exhaustion, lack of
motivation
31 50 m 6025 6025 65 5 1.370 2 7 11 6025m; moderate
AMS
32 44 f 6025 6025 67 4 0.244 0 12 9 5400m;
exhaustion,
moderate AMS
33 69 m 6025 6300 67 5 0.154 0 3 2 6300m;
hypothermia
34 54 m 6025 6450 74 1 0.000 0 0 0 6025m; dyspnoea,
cough, possible
HAPE
35 41 m 5465 5600 77 0 1.023 2 9 12 5600; exhaustion,
lack of motivation
A 24 m 7050 7126 61 7 1.478 3 12 9 summit
B 32 m 7050 7050 54 12 0.766 1 4 2 7050m; exhaustion
C 56 m 7050 7050 52 10 0.386 0 3 4 7050m; severe
dyspnoea, possible
HAPE
AMS-c, cerebral score of the environmental symptoms questionnaire score; AMS-LL, acute mountain sickness according to Lake Louise AMS protocol;
BC, basecamp, C1–3; camps 1–3; IQR, interquartile range; SpO2, pulse oximetric arterial oxygen saturation.
doi:10.1371/journal.pone.0141097.t001
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to camp 3. No significant change in body weight occurred when comparing measurements
before and after altitude stay (p = 0.371).
Imaging findings
Image quality was considered excellent throughout all sequences. On baseline MRI 16 subjects
had noWML. In 22 subjects small focal WML were observed, the number ranging from 1–10
Fig 1. Oxygen saturation of all climbers during the expedition.Oxygen saturation measured by pulse oximetry of all climbers during the expedition.
Oxygen saturation measurements of subjects with new findings in post-expedition MRI are indicated in color.
doi:10.1371/journal.pone.0141097.g001
Table 2. Oxygen saturation and reported AMS scores at different altitudes.
BC (4800m) C1 (5650m) C2 (6025m) C3 (7050m) signiﬁcance
oxygen saturation (%) 84 (IQR 81–87) 79 (IQR 75–82) 72 (IQR 69–76) 65 (IQR 59–67) p < 0.0001
AMS-c 0.0 (IQR 0–0) 0.0 (IQR 0–0.09) 0.09 (IQR 0–0.40) 0.34 (IQR 0.12–0.62) p < 0.0001
% AMS-c 0.7 2.6 1.8 12.7 21.4 p < 0.0001
AMS LL 0.0 (IQR 0–0) 0.0 (IQR 0–0) 0.0 (IQR 0–3) 0.0 (IQR 0–1.5) p < 0.0001
% AMS LL 3 7.0 10.6 28.2 21.4 p < 0.0001
AMS-c, cerebral score of the environmental symptoms questionnaire score; AMS-LL, acute mountain sickness according to Lake Louise AMS protocol;
BC, basecamp, C1–3; camps 1–3; IQR, interquartile range; SpO2, pulse oximetric arterial oxygen saturation.
doi:10.1371/journal.pone.0141097.t002
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(n = 14), 11–20 (n = 5), and 20–30 lesions (n = 3). All of these lesions were small, most
1mm, not confluent, mostly located in the subcortex or deep white matter, and considered to
be of no clinical importance. There was a significant correlation between subject age but not
number of nights spent above 4000m previous to study inclusion and number of WML at base-
line (R square 0.153, p = 0.015 and R square 0.0002, p = 0.9285, respectively). On follow-up
imaging the number of WML remained unchanged in all 38 subjects, no new lesions were
observed.
Fig 2 shows the distribution of the PVE fractions at baseline and PVE fraction changes
between baseline and post-expedition testing. Compared to baseline testing, we observed a sig-
nificant mean CSF fraction change (0.34% [95% CI 0.10–0.58], p = 0.006) and a significant
meanWM fraction change (-0.18% [95% CI -0.32–-0.04], p = 0.012), whereas the mean GM
fraction remained stable (mean change -0.16% [95% CI -0.46–0.13], p = 0.278). The expected
physiological mean PVE changes due to aging were outside of the observed lower and upper
95% CI limits for CSF and WM fraction changes. After correction for multiple comparisons,
no significant correlations between PVE fraction changes and subject characteristics, body
weight changes or parameters determined by severity of hypoxia were observed.
On post-expedition MRI one subject (subject A) presented a new solitary hypointense sple-
nial lesion with the same imaging characteristics described above, compatible with a micro
hemorrhage. Two subjects showed multiple new focal hypointensities in the splenium of the
corpus callosum, not apparent on T1- and T2-weighted images, on post-expedition imaging
suggestive of multiple microhemorrhages. Subject B also showed faint new signal hypointensi-
ties in the corpus and genu of the corpus callosum. No microbleeds in other regions of the
brain were detected (Fig 3). Subjects with new microhemorrhages after the expedition had a
significantly higher maximal sleep altitude (p = 0.048), and significantly lower minimal
recorded SpO2 values (p = 0.007), and a higher number of days with reported SpO2 values
below 75% than subjects with unaltered MRI (p = 0.007). Maximal AMS-c and AMS LL scores
and total number of days with AMS scores above the diagnostic cut-off did not differ between
subjects with and without new microhemorrhages (Table 3).
Discussion
The present study evaluating the occurrence of structural cerebral changes in a cohort of 38
recreational high altitude climbers has three main findings. We did not detect structural
changes indicating brain damage due to chronic hypoxia at altitude, such as WM hyperintensi-
ties or global cortical atrophy. We documented a small but significant decrease in global WM
volume after prolonged hypobaric hypoxia. Post-expedition MRI revealed one subject with a
solitary microhemorrhage and two subjects with multiple new microhemorrhages in the sple-
nium of the corpus callosum. None of these subjects had experienced clinical symptoms of
cerebral dysfunction indicative of HACE during altitude exposure. All three climbers had
spent a night at an altitude above 7000m and reported significantly lower minimal SpO2 values,
more days with SpO2 values lower than 75% but not higher AMS scores than climbers with
unaltered post-expedition MRI.
Our study has a number of limitations. Less than 45% of climbers reached an altitude of
more than 7000 m. The majority of subjects only attained altitudes between 5645 m and 6900
m for various reasons including altitude illnesses, exhaustion and injuries. The applied AMS
scoring systems for identifying the presence and severity of AMS depend on the subjective rat-
ing of the severity of symptoms by the afflicted person. Despite their widespread use it has
been disputed whether these scoring systems can accurately diagnose AMS [14, 15] and studies
comparing different scoring systems revealed differences in scoring results [19]. Additionally,
Brain Changes after Climbing to Extreme Altitudes
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AMS susceptibility is influenced by age which may have influenced AMS incidence in our
cohort with a large age range. We did not perform serial post-expedition MRI. We therefore
cannot exclude that WM or GM changes had already resolved before or occurred after post-
expedition MRI, nor can we determine if the observed reduction in WM fraction is reversible
in the long-term. Our findings are based on the comparison of MRI before and after a single
episode of hypobaric hypoxia and cannot be generalized to repetitive exposure. Our results are
generalizable to the general population of non-elite, recreational high altitude climbers and
trekkers participating in sojourns that include camps not higher than 7000 m and without the
use of oxygen. We assume that the generalizability of our findings can be extended to include
Fig 2. Partial volume estimate fractions at baseline and changes between baseline and post-expedition imaging. Top: Age dependence of the
percentages of the partial volume estimates for cerebro-spinal fluid, grey matter and white matter during baseline testing. Means and standard deviations are
reported at the bottom of the panels. Bottom: Partial volume estimates fraction change between baseline and post-expedition imagining as a function of age.
Means and standard deviations are reported at the bottom of the panels. At the top of the panels the results of a one-sample t-test of the hypothesis that the
mean PVE change is zero are given.
doi:10.1371/journal.pone.0141097.g002
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subjects climbing at higher altitudes, provided that supplementary oxygen is used to avoid
more severe hypoxic conditions.
Only a few studies have examined the possible effect of severe hypobaric hypoxia on cere-
bral structural integrity. In two studies with a transversal design (comparison to a matched
Fig 3. Imaging findings pre- and post-expedition in subjects with newmicrohemorrhages after the climb. Subject A: Comparison of SWI (MinIP) in
pre- and post-expedition MRI shows a new solitary microhemorrhage (indicated by arrow). SWI of Subject B and SWI (MinIP) of subject C showmultiple new
microhemorrhages of the corpus callosum visible in post-expedition MRI (arrows).
doi:10.1371/journal.pone.0141097.g003
Table 3. Comparison of subjects with and without newMRI findings.
Age
(years)
Gender Maximal
sleeping
altitude (m)
Maximal
altitude
reached (m)
Lowest
SaO2 (%)
Number of
days
SpO2<75%
Maximal
AMS-c
Number of
days AMS-c
>0.7
Maximal
AMS LL
Number of
days AMS
LL >2
Signiﬁcance 0.297 0.152 0.048 0.168 0.007 0.007 0.959 0.405 0.959 0.644
AMS-c, cerebral score of the environmental symptoms questionnaire score; AMS-LL, acute mountain sickness according to Lake Louise AMS protocol;
SpO2, pulse oximetric arterial oxygen saturation.
doi:10.1371/journal.pone.0141097.t003
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group of non-climbers), Garrido et al. described findings of cortical atrophy and periventricu-
lar T2-hyperintensities in groups of 26 and 21 mountain climbers ascending to altitudes of
7000 m and 8000 m [8, 10]. Fayed et al. reported results of MRI in 35 climbers after ascents to
peaks of different heights ranging fromMont Blanc (4810 m) to Mt. Everest (8848 m). In the
majority of these climbers, including in three climbers after ascent to the relatively moderate
altitude of Mont Blanc, occurrence of subcortical lesions and cortical atrophy were reported
after visual evaluation of 5 mm FLAIR and T2-weighted images when compared with non-
climbing controls [7]. Two studies applying a longitudinal design with MRI before and after
high altitude exposure have reported structural cerebral alterations. In 2008 Di Paola et al.
found reduced grey matter density/volume in the left angular gyrus but noWM lesions in 9
professional climbers 8 weeks after ascents to K2 and Mt Everest using voxel-based morphom-
etry on magnetization prepared rapid acquisition gradient echo (MPRAGE), and on T2 and
FLAIR sequences [20]. Garrido et al. reported new high-intensity lesions on T2-weighted
images in the posterior lobes in 2 of 9 climbers after reaching altitudes between 7800 m and
8463 m [9]. Anooshiravani et al. did not detect WM lesions or cortical atrophy in a group of
8 climbers when comparing MRI before and after an ascent to altitudes of up to 7100 m [21].
Interestingly, subcortical WM lesions have also been reported after repeated occupational
exposure to nonhypoxic hypobaria [22]. This indicates that the low ambient pressure at
extreme altitudes per se might be a factor contributing to the development of WM lesions
described in previous studies.
In contrast to T2 and FLAIR images with slice thicknesses of 4–6 mm at MR Field strengths
of 0.5–1.5 Tesla in previous studies, we performed an isotropic 3D FLAIR sequence at 3 Tesla
which is highly sensitive for focal WML. The study at hand examined the largest subject group
included in a longitudinal imaging study so far, even when only considering the subjects who
reached an altitude of more than 7000m. In our subjects, we did not detect evidence for grey
matter atrophy as reported in previous studies. One possible explanation could be that our sub-
jects only reached an altitude of 7126 m compared to the higher altitudes attained by Garridos
and Di Paolas groups [5, 9]
A significant decrease in brain WM fraction, even after correction for physiological aging-
associated changes, was documented in our subjects on post-expedition imaging. This finding
has not yet been reported in the context of prolonged hypobaric hypoxia. White matter alter-
ations have been demonstrated in MRI of patients suffering from obstructive sleep apnea
(OSA). These findings include impairment of fiber integrity throughout the brain but with
more pronounced changes in the cortices, limbic system, pons, and cerebellum tracts [23, 24].
In OSA repeated airway obstructions lead to intermittent nocturnal hypoxic episodes. Simi-
larly, at high altitudes, nocturnal central apnea in the context of periodic breathing leads to
pronounced oxygen desaturation periods [25, 26]. Repeated deoxygenation with apneic epi-
sodes may lead to a number of oxidative and inflammatory processes in OSA patients and
healthy subjects at high altitudes. In both groups, markers of oxidative stress and inflammation
are elevated [25–27] which have been associated with neuronal and glial injury [28]. Further-
more, nutritional factors could potentially contribute to the observed decrease in WM fraction.
Decreases in global WM and GM volumes have been reported in patients suffering from
anorexia nervosa [29, 30] and decreases in GM volumes in subjects participating in a multi-day
ultra-marathon [31]. In both groups WM and GM returned to normal after restoration of
body weight. Lack of appetite and weight loss is common in high altitude climbers [32], but the
duration and extent of body mass reduction is far less severe than in anorexia patients.
Reversible vasogenic edema and microhemorrhages indicating blood-brain barrier disrup-
tion with a predilection for the splenium of the corpus callosum are reported to be a finding
characteristic of HACE [6, 11]. Kallenberg et al., examined 6 subjects after the occurrence of
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AMS and non-fatal HACE and detected microhemorrhages in the corpus callosum in the 3
subjects who had suffered from HACE, but not in the 3 subjects who only had experienced
severe AMS [6]. The same group postulated a high diagnostic specificity for HACE of microhe-
morrhages in the corpus callosum in a later cross-sectional study comparing 37 mountaineers
that had either experienced HACE, HAPE, severe AMS or no high altitude illness [12].
Three of our climbers showed new microhemorrhages in the splenium of the corpus callo-
sum after the climb. Microhemorrhages represent evidence for substantial disruption of the
blood brain barrier which is the most important contributor for development of HACE [33], a
condition associated with a high mortality especially at extreme altitudes where treatment pos-
sibilities are limited. We have to assume that these climbers were at an increased risk for devel-
opment of clinically apparent brain edema. However, none of them demonstrated clinical
symptoms of HACE or severe AMS during the course of the expedition. The lack of reported
symptoms demonstrates that a substantial disruption of the blood-brain barrier can occur in
severe hypoxia without obvious clinical symptoms being detected in the challenging circum-
stances at extreme altitude.
In conclusion, we cannot confirm that a sojourn to extreme altitudes is associated with the
development of focal WM lesions and GM atrophy indicative of long-term cerebral damage in
a majority of climbers. High altitude climbing leads to a decrease in brain WM fraction, possi-
bly caused by the associated prolonged hypoxic and catabolic state. Furthermore, microhemor-
rhages indicative of substantial blood-brain barrier disruption occur in a significant number of
climbers attaining extreme altitudes. In climbers with blood-brain barrier disruption, clinical
symptoms of brain edema can be absent or are missed by the affected climber and their fellow
mountaineers in a state of extreme exhaustion and mental fatigue which is characteristic of
high altitude climbing.
Supporting Information
S1 Table. Oxygen saturation, AMS scores and single AMS items as collected during the
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